Xencor, Inc. has entered into an antibody optimization collaboration with CSL, Ltd., under which CSL will have access to Xencor’s XmAb technology platform to enhance the ADCC effector function of its therapeutic antibodies. Xencor has granted CSL several commercial licenses to move product candidates into development and commercialization that use Xencor’s XmAb technology. In addition to an undisclosed upfront payment, Xencor will receive development milestone payments and product royalties f...